1. Home
  2. ESPR vs EARN Comparison

ESPR vs EARN Comparison

Compare ESPR & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ESPR
  • EARN
  • Stock Information
  • Founded
  • ESPR 2008
  • EARN 2012
  • Country
  • ESPR United States
  • EARN United States
  • Employees
  • ESPR N/A
  • EARN N/A
  • Industry
  • ESPR Biotechnology: Pharmaceutical Preparations
  • EARN Real Estate Investment Trusts
  • Sector
  • ESPR Health Care
  • EARN Real Estate
  • Exchange
  • ESPR Nasdaq
  • EARN Nasdaq
  • Market Cap
  • ESPR 220.0M
  • EARN 223.5M
  • IPO Year
  • ESPR 2013
  • EARN 2013
  • Fundamental
  • Price
  • ESPR $2.17
  • EARN $5.87
  • Analyst Decision
  • ESPR Buy
  • EARN Buy
  • Analyst Count
  • ESPR 6
  • EARN 2
  • Target Price
  • ESPR $6.50
  • EARN $6.13
  • AVG Volume (30 Days)
  • ESPR 5.2M
  • EARN 385.7K
  • Earning Date
  • ESPR 08-05-2025
  • EARN 08-19-2025
  • Dividend Yield
  • ESPR N/A
  • EARN 16.44%
  • EPS Growth
  • ESPR N/A
  • EARN N/A
  • EPS
  • ESPR N/A
  • EARN N/A
  • Revenue
  • ESPR $268,125,000.00
  • EARN $35,893,000.00
  • Revenue This Year
  • ESPR $6.10
  • EARN $3.72
  • Revenue Next Year
  • ESPR N/A
  • EARN $18.59
  • P/E Ratio
  • ESPR N/A
  • EARN N/A
  • Revenue Growth
  • ESPR N/A
  • EARN 43.30
  • 52 Week Low
  • ESPR $0.69
  • EARN $4.33
  • 52 Week High
  • ESPR $3.94
  • EARN $7.11
  • Technical
  • Relative Strength Index (RSI)
  • ESPR 73.45
  • EARN 57.65
  • Support Level
  • ESPR $2.00
  • EARN $5.59
  • Resistance Level
  • ESPR $2.14
  • EARN $5.76
  • Average True Range (ATR)
  • ESPR 0.15
  • EARN 0.12
  • MACD
  • ESPR 0.02
  • EARN 0.02
  • Stochastic Oscillator
  • ESPR 95.08
  • EARN 94.03

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

Share on Social Networks: